While many organizations stop at providing laboratory results, Neeli Genetics has built a layered interpretive framework that spans from molecular insights to therapeutic outcomes
Neeli Dilip Kumar, Director
In India’s oncology corridors, oncologists are increasingly facing a modern conundrum. It’s not the lack of tests, but the deluge of fragmented, hard-to-interpret genomic information that slows decision-making. A physician may receive a report listing dozens of gene mutations, resistance markers, and expression profiles, yet be left with no clear roadmap on what treatment to pursue. This is not a failure of science, but of translation that converts data into decisions. Stepping into this growing void is Neeli Genetics.
Operating at the intersection of science, logistics, and care, Neeli Genetics is a clinical-intelligence firm specializing in precision oncology. It offers a comprehensive suite of services that guide oncologists and patients through the full genomic testing journey, from selecting the appropriate RGCC test panel and ensuring temperature-controlled sample logistics, to interpreting complex omics data and delivering personalized treatment protocols. Founded in 2012 with a vision to bridge global standards with Indian clinical contexts, the company empowers oncologists with real?time clinical intelligence grounded in evidence-based oncology.
Precision Without Fragmentation
Neeli Genetics, through its exclusive partnership with the globally recognized RGCC laboratories, offers what it calls a ‘central dogma’ approach to cancer diagnostics. “Once a patient’s sample is received, we analyze all the relevant data required for clinical decision-making”, says Neeli Dilip Kumar, Director, Neeli Genetics. This includes gene expressions, drug resistance markers, immune system profiling, and tumor stemness, integrated into a single, physician-facing clinical interpretation. “Our platform functions as a central hub, delivering every critical insight needed for that individual case”, Dilip Kumar adds.
The partnership with RGCC also gives the company early access to evolving research in molecular oncology. These advancements are rapidly integrated into its interpretation frameworks, giving Indian clinicians access to insights typically filtered through slower academic dissemination. This is especially critical in the interpretation of genomic, proteomic, and metabolomic data, where the clinical significance is often not self-evident.
While many organizations stop at providing laboratory results, Neeli Genetics has built a layered interpretive framework that spans from molecular insights to therapeutic outcomesNeeli Dilip Kumar, Director
A System, Not a Service
From patient onboarding to post-report consultation, the company functions as a clinical intelligence partner. Its strength is in the continuity where each element, from test requisition to therapeutic guidance, is orchestrated for efficiency and clarity. All protocols are based not just on experimental data but on real-world outcomes.
Neeli Genetics' team comprises cross-disciplinary experts in cancer biology, pharmacogenomics, conventional oncologist team, integrative medicine, and bioinformatics, with a commitment to clinical relevance. From the first point of contact, its clinical advisory team steps in to counsel patients and physicians on which RGCC test panels align with the patient’s cancer type, history, and clinical objectives. This pre-test advisory stage is a technical and ethical prerequisite to personalized oncology. It is a consultative process, intended to contextualize testing within the patient’s journey rather than offering data in isolation.
For hospitals and practitioners, Neeli Genetics offers a reliable, end-to-end, integrative solution that reduces diagnostic ambiguity and speeds up therapeutic decision-making. With a clinically validated turnaround time, test accuracy that meets global benchmarks, and a rich depth of interpretation, it becomes a trusted clinical ally, not just a laboratory vendor.
Demand for Personalization
The company acts a translator that connects the growing patient interest in personalized medicine with actionable, evidence-backed clinical frameworks. Neeli Genetics' network of trained oncologists and clinical partners across institutions ensures that its insights are lived out daily in treatment rooms. Importantly, it invests in physician education, helping practitioners understand the value of molecular-level data through dedicated portals, consultation frameworks, and continuous training programs.
While many organizations stop at providing laboratory results, Neeli Genetics has built a layered interpretive framework that spans from molecular insights to therapeutic outcomes. Its AI-enabled platform, trained on global and India-specific datasets, allows clinicians to understand what markers exist in a tumor, how they interact, what they signify in Indian patient populations, and what the likely clinical response will be.
Precision Logistics
The company has built a dedicated backend system to coordinate sample handling, collection, packaging, documentation, and temperature-controlled global shipping, managed in partnership with DHL. These operational safeguards are designed not for efficiency alone, but for integrity, ensuring that samples reach RGCC’s laboratories under validated conditions and timelines. Temperature, transit, and custody protocols are monitored continuously.
Once testing is complete, the data interpretation process begins, not with software alone, but with an interdisciplinary scientific team. Gene expressions, immune metrics, and drug sensitivity indices are decoded by in-house bioinformaticians, who work closely with treating physicians. Together, they co-construct therapeutic strategies based on actionable insights. If the patient’s response to therapy changes, the company continues to support case evaluations through follow-up consultations.
Expanding the Model of Clinical Intelligence
Neeli Genetics focuses on building informatics tools that make its services more scalable and clinician-friendly. A proprietary AI-powered portal system, now in implementation, allows oncologists to map RGCC test results to treatment options instantly. These tools are being piloted across integrative oncology clinics and hospital systems in India.
Parallely, Neeli Genetics is launching patient-facing digital platforms that help individuals monitor disease progression using their genomic data. Its service lines are also expanding beyond oncology to areas where personalized medicine remains underserved such as autoimmune and neurodegenerative disorders. Educational programs on precision medicine continue in tandem with these expansions, reflecting the company’s view that technology alone cannot drive adoption without clinician engagement.
As genomics, AI, and systems biology evolve, Neeli Genetics continues to evolve with them, grounding innovation in medical application. The ambition is scale and precision, delivered with accountability. By interpreting diagnostics in an integrative, patient?focused manner, it can be a strategic partner helping to drive precision medicine in India.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
